

DT07 Rec'd PCT/PTO 3 1 JAN 2005

Certificate of Mailing

Date of Deposit: January 31, 2005Label Number: EV544139466US

I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Elvis De La Cruz

Printed name of person mailing correspondence

Signature of person mailing correspondence

Substitute Form PTO 1390 U.S. Department of Commerce Patent and Trademark Office

Attorney Docket Number:

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. § 371

50304/059001

U.S. Application Number:

10/523444

INTERNATIONAL APPLICATION NUMBER

INTERNATIONAL FILING DATE

PRIORITY DATE CLAIMED

PCT/EP03/008365

July 28, 2003

July 31, 2002

TITLE OF INVENTION:


ANTI-IDIOTYPIC ANTIBODIES AGAINST FACTOR VIII INHIBITOR AND USES THEREOF

APPLICANTS FOR DO/EO/US:

GILLES et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a FIRST submission of items concerning a filing under 35 U.S.C. § 371.
2. ☐ This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. § 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. § 371(f)).
4. ☒ The U.S. has been elected.
5. A copy of the International Application (35 U.S.C. § 371(c)(2)).
 - ☒ a. is transmitted herewith (required only if not transmitted by the International Bureau).
 - ☐ b. has been transmitted by the International Bureau.
 - ☐ c. is not required, as the application was filed with the United States Receiving Office (RO/US).
6. An English language translation of the International Application into English (35 U.S.C. § 371(c)(2)).
 - ☐ a. is transmitted herewith.
 - ☐ b. has been previously submitted under 35 U.S.C. 154(d)(4).
7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. § 371(c)(3)).
 - ☐ a. are transmitted herewith (required only if not transmitted by the International Bureau).
 - ☐ b. have been transmitted by the International Bureau.
 - ☐ c. have not been made; however, the time limit for making such amendments has NOT expired.
 - ☒ d. have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. § 371(c)(3)).
9. ☒ An oath or declaration of the inventors (unsigned) (35 U.S.C. § 371(c)(4)).
10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. § 371 (c)(5)).
11. ☒ An Information Disclosure Statement under 37 C.F.R. §§ 1.97 and 1.98.
12. ☐ An assignment for recording. A separate cover sheet in compliance with 37 C.F.R. §§ 3.28 and 3.31 is included.
13. ☒ A preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A power of attorney and/or change of address letter.
16. ☐ Request for Deferred Examination.
17. ☒ Application Data Sheet.
18. ☒ Other items or information: WO 2004/014955 A1 (65pgs.); PCT Request (PCT/RO/101) (6pgs); Indications Relating to Deposited Microorganism (PCT/RO/134) (5pgs); International Search Report (PCT/ISA/210) (6pgs); International Preliminary Examination Report (PCT/IPEA/416) (16pgs.); Sequence Listing (5pgs.); Sequence Statement (2pgs.); and Diskette

19. <input checked="" type="checkbox"/> The following fees are submitted:					
Basic National Stage Fee \$300				\$300.00	
National Stage Search Fee: \$500				\$500.00	
National Stage Examination Fee: \$200				\$200.00	
Surcharge of \$130 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 C.F.R. § 1.492(e)).				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	16 - 20 =	0	x \$50	\$	
Independent claims	4 - 3 =	1	x \$200	\$200.00	
Multiple dependent claims (if applicable)			+ \$360	\$	
Application Size Fee: Additional fee for specification and drawings in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.					
TOTAL SHEETS	EXTRA SHEETS	Number of each additional 50 sheets or fraction thereof (round up to a whole number)	RATE		
65 - 100 =	0/50 =		X\$250	\$	
TOTAL OF ABOVE CALCULATIONS =				\$1,200.00	
Reduction of 1/2 for filing by small entity, if applicable. Applicant claims small entity status under 37 C.F.R. § 1.27				\$	
SUBTOTAL =				\$600.00	
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 C.F.R. § 1.492(f)).				+	\$
TOTAL NATIONAL FEE =				\$600.00	
Fee for recording the enclosed assignment (37 C.F.R. 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 C.F.R. §§ 3.28, 3.31). \$40.00 per property.				+	\$
TOTAL FEES ENCLOSED =				\$600.00	
				Amount to be refunded	\$
				charged	\$
<input checked="" type="checkbox"/> a. Enclosed is a check for \$600.00 to cover the total fees. <input type="checkbox"/> b. Enclosed is a check for [**\$300/\$150**] to cover the basic national stage fee; no other fees are being paid at this time. <input type="checkbox"/> c. Please charge my Deposit Account No. 03-2095 in the amount of \$[**] to cover the above fees. <input checked="" type="checkbox"/> d. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Deposit Account No. 03-2095.					
NOTE: Where an appropriate time limit under 37 C.F.R. §§ 1.494 or 1.495 has not been met, a petition to revive (37 C.F.R. § 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO:					
James D. DeCamp, Ph.D. Clark & Elbing LLP 101 Federal Street Boston, MA 02110-2214 Telephone: 617-428-0200 Facsimile: 617-428-7045 Customer No.: 21559			 Signature James D. DeCamp, Ph.D. Reg. No. 43,580		